Tiotropium
- Generic Name
- Tiotropium
- Brand Names
- Inspiolto Respimat, Spiriva, Spiriva Respimat, Stiolto
- Drug Type
- Small Molecule
- Chemical Formula
- C19H22NO4S2
- CAS Number
- 186691-13-4
- Unique Ingredient Identifier
- 0EB439235F
- Background
Tiotropium is a long-acting, antimuscarinic bronchodilator used in the management of chronic obstructive pulmonary disease (COPD) and asthma. Tiotropium acts mainly on M3 muscarinic receptors located in the airways to produce smooth muscle relaxation and bronchodilation.
...
- Indication
Tiotropium powder for inhalation is indicated for the maintenance of bronchospasm in COPD and to prevent exacerbations of COPD. A combination tiotropium and olodaterol metered inhalation spray is indicated for maintenance of COPD. A tiotropium inhalation spray is indicated for the maintenance of bronchospasm in COPD, to prevent exacerbations of COPD, and to ...
- Associated Conditions
- Asthma, Bronchitis, Bronchoconstriction, Chronic Bronchitis, Chronic Obstructive Pulmonary Disease (COPD), Emphysema, Exacerbation of COPD
- Associated Therapies
- -
Tiotropium/Formoterol Via Discair® vs Tiotropium Monotherapy or Tiotropium + Formoterol Free Combination Treatment
- Conditions
- Interventions
- First Posted Date
- 2016-12-09
- Last Posted Date
- 2020-06-16
- Lead Sponsor
- Neutec Ar-Ge San ve Tic A.Ş
- Target Recruit Count
- 84
- Registration Number
- NCT02988869
- Locations
- 🇹🇷
Yedikule Chest Diseases and Thoracic Surgery Training and Research Hospital, Istanbul, Turkey
Bioavailability of Tiotropium + Olodaterol Fixed-dose Combination (5 μg/ 5 μg) in Chinese COPD Patients
- Conditions
- Interventions
- First Posted Date
- 2016-11-21
- Last Posted Date
- 2019-03-29
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 12
- Registration Number
- NCT02969317
- Locations
- 🇨🇳
West China Hospital, Chengdu, China
Effects of Long Acting Bronchodilators on CARDiac Autonomic Control in Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- Interventions
- First Posted Date
- 2016-08-18
- Last Posted Date
- 2021-08-03
- Lead Sponsor
- Centre Hospitalier Universitaire de Besancon
- Target Recruit Count
- 42
- Registration Number
- NCT02872090
- Locations
- 🇫🇷
Centre Hospitalier Régional Universitaire, Besançon, France
Effect of Tiotropium + Olodaterol on Breathlessness in COPD Patients
- Conditions
- Interventions
- First Posted Date
- 2016-08-02
- Last Posted Date
- 2019-09-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 106
- Registration Number
- NCT02853123
- Locations
- 🇧🇪
Hasselt - PRAC Aumann, J-L, Hasselt, Belgium
🇨🇦McGill University Health Centre (MUHC), Montreal, Quebec, Canada
🇨🇦McMaster Univ. Medical Centre, Hamilton, Ontario, Canada
Fixed Dose Combination Versus Free Combination of Tiotropium and Olodaterol in COPD
- Conditions
- Interventions
- First Posted Date
- 2016-02-17
- Last Posted Date
- 2018-08-17
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 221
- Registration Number
- NCT02683109
- Locations
- 🇦🇹
Ordination Dr. Robert Voves, 8330 Feldbach, Feldbach, Austria
🇦🇹KH d. Elisabethinen Linz, Linz, Austria
🇩🇰Aarhus Universitetshospital, Aarhus, Denmark
Cross-over Study in Volunteers to Compare the Pharmacokinetics of Tiotropium Delivered From Test and Reference Products
- First Posted Date
- 2016-02-08
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Solventum US LLC
- Target Recruit Count
- 26
- Registration Number
- NCT02676297
- Locations
- 🇬🇧
Quotient Clinical Ltd, Ruddington, Nottingham, United Kingdom
Comparing the Efficacy of Tiotropium + Olodaterol Fixed Dose Combination (FDC) Over Tiotropium in Improvement of Lung Hyperinflation, Exercise Capacity and Physical Activity in Japanese COPD Patients
- Conditions
- Interventions
- First Posted Date
- 2015-12-15
- Last Posted Date
- 2019-06-06
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 184
- Registration Number
- NCT02629965
- Locations
- 🇯🇵
Tohno Chuo Clinic, Gifu, Mizunami, Japan
🇯🇵Kirigaoka Tsuda Hospital, Fukuoka, Kitakyushu, Japan
🇯🇵Nishi Fukuoka Hospital, Fukuoka, Fukuoka, Japan
Comparison of the Pharmacokinetics of Tiotropium Delivered From Test Inhaler Products With Two Reference Products
- First Posted Date
- 2015-12-11
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Solventum US LLC
- Target Recruit Count
- 31
- Registration Number
- NCT02627625
- Locations
- 🇬🇧
Quotient Clinical Ltd, Ruddington, Nottingham, United Kingdom
Duration of Long Acting Muscarinic Antagonist (LAMA) Bronchoprotection Against Methacholine Challenge
- Conditions
- Interventions
- First Posted Date
- 2015-12-04
- Last Posted Date
- 2016-04-20
- Lead Sponsor
- University of Saskatchewan
- Target Recruit Count
- 13
- Registration Number
- NCT02622243
- Locations
- 🇨🇦
Asthma Research Lab, Saskatoon, Saskatchewan, Canada
Evaluation of the Efficacy and Safety of QVA149 (110/50 μg o.d.) vs Tiotropium (18 µg o.d.) + Salmeterol/Fluticasone Propionate FDC (50/500 µg b.i.d.) in Patients With Moderate to Severe COPD
- Conditions
- Interventions
- First Posted Date
- 2015-11-11
- Last Posted Date
- 2019-04-29
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 1053
- Registration Number
- NCT02603393
- Locations
- 🇬🇧
Novartis Investigative Site, Wolverhampton, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.